Quest Diagnostics Appoints Timothy Wentworth as Director
Quest Diagnostics has elected Timothy Wentworth to serve as a director. Including Wentworth, the company's board has eleven members. Wentworth was most recently CEO of Walgreens Boots Alliance. Prior to that, he was founding CEO of Evernorth Health Services, the health services organization of The Cigna Group. In addition, Wentworth was president and CEO of Express Scripts, one of the largest pharmacy benefit managers in the United States. Wentworth's experience also includes senior leadership roles with consumer brands, including COO at Mary Kay, and director roles in human resources at PepsiCo. Wentworth serves on the boards of directors of Walgreens Holding and Dfinitiv, and previously served on the boards of Walgreens Boots Alliance, Accredo Health Group, Express Scripts, and Forge Health.
Trade with 70% Backtested Accuracy
Analyst Views on DGX
About DGX
About the author

- Earnings Release Schedule: Quest Diagnostics will report its Q1 2026 financial results on April 21, 2026, before market open, which is expected to significantly impact investors and the market.
- Conference Call Details: The company will hold a conference call at 8:30 a.m. Eastern Time on the same day, allowing investors to dial in at 888-455-0391 (U.S. and Canada) or 773-756-0467 (international) to receive timely financial information.
- Replay Access: A replay of the conference call will be available starting at 10:30 a.m. Eastern Time on April 21, 2026, until midnight on May 5, providing a convenient way for investors who missed the live event to access key information.
- Company Background: Quest Diagnostics plays a crucial role in the U.S. healthcare sector, serving one in three American adults annually, emphasizing its strategic significance in improving health management and disease identification.
- AI Companion Feature: Quest Diagnostics has launched the Quest AI Companion, powered by Google's Gemini technology, which analyzes up to five years of personal lab data to help users understand test results and identify potential health risks, thereby enhancing communication efficiency between patients and healthcare providers.
- User Experience Enhancement: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their results through simple inquiries, thus avoiding the privacy risks associated with uploading personal health data to public AI platforms and increasing user trust in data security.
- Strategic Collaboration: The strategic partnership between Quest and Google Cloud was established in March 2025, aiming to integrate advanced AI technologies to optimize data management and customer experience, with plans for continued collaboration to drive healthcare innovation and improve service quality for patients and providers.
- Market Demand Response: Despite the growing prevalence of AI technologies in healthcare, a Quest survey indicates that most individuals are cautious about using public AI applications to analyze personal health data; the launch of Quest AI Companion addresses patients' needs for privacy and data security, helping them better understand their lab data.
- AI Companion Launch: Quest Diagnostics introduces Quest AI Companion, powered by Google's Gemini technology, which helps users analyze up to five years of lab data to identify potential health risks, thereby enhancing user engagement and proactive health management.
- Enhanced User Experience: This feature is now available to all adult users through the MyQuest app, allowing individuals to receive personalized explanations of their lab results through simple inquiries, which improves communication efficiency between patients and healthcare providers.
- Data Security Assurance: Operating within the HIPAA-compliant MyQuest platform, Quest AI Companion alleviates concerns about uploading personal health data to public AI platforms, effectively safeguarding privacy and increasing user trust.
- Deepened Strategic Partnership: The strategic collaboration between Quest and Google Cloud, established in March 2025, aims to optimize data management and customer experience through the integration of advanced AI technologies, with plans to continue driving healthcare innovation.
- Graduation Announcement: DIGI POWER X graduates are set to become part of the Canadian workforce, marking a significant milestone in their educational journey.
- Program Impact: The program aims to equip graduates with essential skills and knowledge to thrive in the energy sector, contributing to Canada's growing demand for skilled professionals.
- Future Opportunities: Graduates are expected to explore various career paths within the energy industry, enhancing their prospects in a competitive job market.
- Community Engagement: The graduation event highlights the importance of community support and collaboration in fostering educational initiatives and workforce development.
- Executive Appointment: Quest Diagnostics has appointed Benjamin Beauvalot as Senior Vice President and Chief Strategy and M&A Officer, responsible for developing the company's growth strategy and leading mergers and acquisitions, which is expected to drive further advancements in the healthcare sector.
- Extensive Experience: Beauvalot brings over 20 years of experience in business strategy and transformation, having held executive roles at Danaher and Patheon where he successfully implemented numerous M&A and integration strategies, enhancing his expertise in the healthcare services field.
- Leadership Transition: Beauvalot succeeds Dermot Shorten, who has held the position since 2008 and oversaw nearly 80 business combinations and collaborations, including approximately 20 acquisitions of hospital outreach laboratories, establishing a solid foundation for the company.
- Strategic Vision: The new Chief Strategy Officer's appointment aims to leverage his rigorous approach to business integration to further propel Quest Diagnostics' organic and acquisitive growth, supporting the company's mission to create a healthier world.
- Strategic Speaking Engagement: Quest Diagnostics' CFO Sam Samad is scheduled to speak at the Leerink 2026 Global Healthcare Conference in Miami on March 11, 2026, where he will discuss the company's strategy, performance, and latest market developments, likely drawing attention from investors and industry experts.
- Live Webcast and Replay: The Fireside Chat and Q&A session will be webcast live on the company's investor relations page, with an archived version available within 24 hours post-event and accessible until March 25, 2026, ensuring that investors unable to attend live can still access the information.
- Company Overview: Quest Diagnostics plays a crucial role in the U.S. healthcare sector, serving one in three American adults annually, connecting clinicians and consumers, and focusing on smarter, simpler testing to enhance health management and drive disease identification and treatment.
- Employee and Service Reach: With nearly 57,000 employees, the company serves half of the physicians and hospitals in the U.S., providing diagnostic insights that inspire actions aimed at improving quality of life, reflecting its leadership position in the healthcare industry.







